Four SGLT2 inhibitors, empagliflozin (Jardiance), dapagliflozin (Forxiga), canagliflozin (Invokana), and ertugliflozin (Stelagro) have recently been approved for the treatment of type 2 diabetes mellitus by the US Food and Drug Administration, and are associated with beneficial effects in the cardiovascular system and the kidney [74]. This evidence concerns the gene SLC5A2 and diabetes mellitus.